Ovid Therapeutics raises $53.9M from warrant exercise

Ovid Therapeutics Inc. reported that its Series A Warrants issued in an October 2025 private placement expired on April 17, 2026.

Rhea-AI Filing Summary

Ovid Therapeutics Inc. reported that its Series A Warrants issued in an October 2025 private placement expired on April 17, 2026. Holders elected to exercise warrants into 33,597,860 common shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per warrant.

These exercises covered most of the 38,481,325 common shares underlying the Series A Warrants and generated approximately $53.9 million in gross cash proceeds for the company.

Insights

Biotech capital structure analyst

Warrant exercises convert derivatives into equity and add $53.9M cash.

The expiration of Ovid Therapeutics’ Series A Warrants led investors to exercise rights for 33,597,860 common shares at $1.40 and 4,883,464 pre-funded warrants at $1.399. This converts a large derivative overhang into equity and pre-funded instruments.

The company received approximately $53.9 million in gross proceeds, providing additional cash resources. The underlying pool was 38,481,325 common shares as of the warrant expiry on April 17, 2026, indicating high take-up by investors.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Gross proceeds from exercises: $53.9 million Underlying Series A Warrant pool: 38,481,325 shares Common shares issued: 33,597,860 shares +4 more

7 metrics

Gross proceeds from exercises $53.9 million From Series A Warrant exercises upon expiry on April 17, 2026

Underlying Series A Warrant pool 38,481,325 shares Aggregate number of common shares underlying Series A Warrants

Common shares issued 33,597,860 shares Exercised from Series A Warrants at $1.40 per share

Pre-funded warrants issued 4,883,464 pre-funded warrants Exercised from Series A Warrants at $1.399 per warrant

Common share exercise price $1.40 per share Exercise price for common stock under Series A Warrants

Pre-funded warrant exercise price $1.399 per warrant Exercise price for pre-funded warrants from Series A Warrants

Warrant expiry date April 17, 2026 Expiration date of Ovid’s Series A Warrants

Key Terms

Series A Warrants, pre-funded warrants, private placement, gross proceeds

4 terms

Series A Warrants financial

"On April 17, 2026, the Series A Warrants (the “Series A Warrants”) issued by Ovid Therapeutics Inc."

Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.

pre-funded warrants financial

"and 4,883,464 pre-funded warrants for $1.399 per share, resulting in gross proceeds"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

private placement financial

"Series A Warrants issued by Ovid Therapeutics Inc. in connection with its October 2025 private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

gross proceeds financial

"for $1.40 per share and 4,883,464 pre-funded warrants for $1.399 per share, resulting in gross proceeds to the Company"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/20/2026 - 08:16 AM EDT Learn about SEC filing dates

0001636651false00016366512024-03-082024-03-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2026

Ovid Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38085			46-5270895
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)
441 Ninth Avenue, 14th Floor New York, New York						10001
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646-661-7661

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

OVID

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Item 8.01    Other Events.

On April 17, 2026, the Series A Warrants (the “Series A Warrants”) issued by Ovid Therapeutics Inc. (the “Company”) in connection with its October 2025 private placement expired. The aggregate number of common shares underlying the Series A Warrants was 38,481,325, and investors elected to exercise the warrants into 33,597,860 shares of the Company’s common stock for $1.40 per share and 4,883,464 pre-funded warrants for $1.399 per share, resulting in gross proceeds to the Company of approximately $53.9 million.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 20, 2026
			OVID THERAPEUTICS INC.
			By:			/s/ Jeffrey Rona
						Jeffrey Rona
						Chief Business and Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.7 KB